Credit Suisse upgrades Dr Reddy's on U.S. outlook
Reuters Market Eye - Credit Suisse upgrades Dr. Reddy's Laboratories(REDY.NS) to 'outperform' from 'neutral' and raises its target price to 2,150 rupees from 1,900 rupees, citing expectations for a strong pick up in U.S. sales in the coming quarters.
Credit Suisse also notes the market share for Dr. Reddy's Metoprolol drug, used for hypertension, is increasing.
Dr. Reddy's also expects upcoming approval of two limited competition products in the United States, Credit Suisse says after meeting with the drug maker's management.
Dr. Reddy's also expects fiscal 2015 growth in the United States to be stronger than fiscal 2014 due to some "significant" launches.
- Tweet this
- Share this
- Digg this
Trending On Reuters
South Asian nations will sign a deal on Thursday to create a seamless electricity grid, Nepal's foreign minister said, signalling an agreement to salvage a regional summit that had been overshadowed by hostilities between India and Pakistan. Full Article | Slideshow